April 29 - Breakingviews columnists discuss the U.S. drug giant’s hankering for AstraZeneca and whether more so-called inversion deals will follow suit.
01:55
01:16
01:12
01:36
03:01
01:42
00:44
01:12
01:52
02:37
01:20
01:01
01:18
00:56
02:34
00:53
02:07
02:14
01:22
02:25
01:03
01:12
01:55
00:25
01:57
01:31
02:50
01:31
00:49
01:57
00:50
01:22
01:12
01:04
03:00
01:04
02:43
01:31
00:53
03:14
00:54
00:54
00:31
01:49
03:43
00:49
02:06
00:39
03:04
00:58
01:07
01:38
00:45
01:10
01:04
02:19
00:59
00:14
01:05
01:14
01:16
01:30
03:01
01:03
04:26
01:31
01:16
01:05
01:43
01:28
01:09
01:03
01:42
01:20
02:34
01:46
01:55
03:58
01:24
01:19
01:20
01:42
00:52
04:06
03:26
00:31
01:10
03:18
01:18
01:20
01:24
01:30
02:00
01:26
02:13
01:21
01:54
01:00
01:42
03:46
02:06
02:14
01:50
01:14
02:02
01:25
02:18
01:11
02:13
01:39
01:52
02:03
01:28
01:37
01:36
01:11
00:47
01:15
01:46
01:48